论文信息 - Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations - 字舞流文

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

Y. Drew | R. Plummer | N. Tunariu | Juanita Lopez | U. Banerji | T. Yap | F. Raynaud | E. Hall | S. Carreira | R. Kristeleit | J. Bono | B. Basu | J. Lindemann | S. Kumar | P. Rugman | D. Roda | V. Michalarea | R. Roux | H. Shaw | B. O’Carrigan | M. Pass | M. Cullberg | M. Parmar | A. Turner | A. Foxley | Raquel Perez | S. Ward | S. S. Fandos | B. O'Carrigan